112 related articles for article (PubMed ID: 26895851)
1. Expression and prognostic significance of ELL-associated factor 2 in human prostate cancer.
Zang Y; Dong Y; Yang D; Xue B; Li F; Gu P; Zhao H; Wang S; Zhou S; Ying R; Wang Z; Shan Y
Int Urol Nephrol; 2016 May; 48(5):695-700. PubMed ID: 26895851
[TBL] [Abstract][Full Text] [Related]
2. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
[TBL] [Abstract][Full Text] [Related]
3. Men presenting with prostate-specific antigen (PSA) values of over 100 ng/mL.
Ang M; Rajcic B; Foreman D; Moretti K; O'Callaghan ME
BJU Int; 2016 Apr; 117 Suppl 4():68-75. PubMed ID: 26890320
[TBL] [Abstract][Full Text] [Related]
4. Conditional Deletion of Eaf1 Induces Murine Prostatic Intraepithelial Neoplasia in Mice.
Pascal LE; Su F; Wang D; Ai J; Song Q; Wang Y; O'Malley KJ; Cross B; Rigatti LH; Green A; Dhir R; Wang Z
Neoplasia; 2019 Aug; 21(8):752-764. PubMed ID: 31229879
[TBL] [Abstract][Full Text] [Related]
5. Concomitant loss of EAF2/U19 and Pten synergistically promotes prostate carcinogenesis in the mouse model.
Ai J; Pascal LE; O'Malley KJ; Dar JA; Isharwal S; Qiao Z; Ren B; Rigatti LH; Dhir R; Xiao W; Nelson JB; Wang Z
Oncogene; 2014 May; 33(18):2286-94. PubMed ID: 23708662
[TBL] [Abstract][Full Text] [Related]
6. Combined Loss of EAF2 and p53 Induces Prostate Carcinogenesis in Male Mice.
Wang Y; Pascal LE; Zhong M; Ai J; Wang D; Jing Y; Pilch J; Song Q; Rigatti LH; Graham LE; Nelson JB; Parwani AV; Wang Z
Endocrinology; 2017 Dec; 158(12):4189-4205. PubMed ID: 29029019
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of Golgi phosphoprotein-3 is associated with tumor aggressiveness and poor prognosis of prostate cancer.
Hua X; Yu L; Pan W; Huang X; Liao Z; Xian Q; Fang L; Shen H
Diagn Pathol; 2012 Sep; 7():127. PubMed ID: 23006319
[TBL] [Abstract][Full Text] [Related]
8. CD151 protein expression predicts the clinical outcome of low-grade primary prostate cancer better than histologic grading: a new prognostic indicator?
Ang J; Lijovic M; Ashman LK; Kan K; Frauman AG
Cancer Epidemiol Biomarkers Prev; 2004 Nov; 13(11 Pt 1):1717-21. PubMed ID: 15533898
[TBL] [Abstract][Full Text] [Related]
9. EAF2 and p53 Co-Regulate STAT3 Activation in Prostate Cancer.
Pascal LE; Wang Y; Zhong M; Wang D; Chakka AB; Yang Z; Li F; Song Q; Rigatti LH; Chaparala S; Chandran U; Parwani AV; Wang Z
Neoplasia; 2018 Apr; 20(4):351-363. PubMed ID: 29518696
[TBL] [Abstract][Full Text] [Related]
10. ELL binding regulates U19/Eaf2 intracellular localization, stability, and transactivation.
Xiao W; Jiang F; Wang Z
Prostate; 2006 Jan; 66(1):1-12. PubMed ID: 16114057
[TBL] [Abstract][Full Text] [Related]
11. Overexpressed Rce1 is positively correlated with tumor progression and predicts poor prognosis in prostate cancer.
Huang L; Li M; Wang D; He J; Wu W; Zeng Q; Li J; Xiao M; Hu J; He Y; Li Y; Mai L; Liu W
Hum Pathol; 2016 Jan; 47(1):109-14. PubMed ID: 26546252
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
Saito T; Hara N; Kitamura Y; Komatsubara S
Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
[TBL] [Abstract][Full Text] [Related]
13. CD10 is inversely associated with nuclear factor-kappa B and predicts biochemical recurrence after radical prostatectomy.
Voutsadakis IA; Vlachostergios PJ; Daliani DD; Karasavvidou F; Kakkas G; Moutzouris G; Melekos MD; Papandreou CN
Urol Int; 2012; 88(2):158-64. PubMed ID: 22286396
[TBL] [Abstract][Full Text] [Related]
14. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical expression of transforming growth factor beta 1 and nm-23 H1 antioncogene in prostate cancer: divergent correlation with clinicopathological parameters.
Stravodimos K; Constantinides C; Manousakas T; Pavlaki C; Pantazopoulos D; Giannopoulos A; Dimopoulos C
Anticancer Res; 2000; 20(5C):3823-8. PubMed ID: 11268461
[TBL] [Abstract][Full Text] [Related]
16. Apoptosis induction and growth suppression by U19/Eaf2 is mediated through its ELL-binding domain.
Hahn J; Xiao W; Jiang F; Simone F; Thirman MJ; Wang Z
Prostate; 2007 Feb; 67(2):146-53. PubMed ID: 17044034
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in metastatic prostate cancer.
Yigitbasi O; Ozturk U; Goktug HN; Gucuk A; Bakirtas H
Urol Oncol; 2011; 29(2):162-5. PubMed ID: 19450995
[TBL] [Abstract][Full Text] [Related]
18. Epithelial cell adhesion molecule-positive circulating tumor cells as predictive biomarker in patients with prostate cancer.
Amato RJ; Melnikova V; Zhang Y; Liu W; Saxena S; Shah PK; Jensen BT; Torres KE; Davis DW
Urology; 2013 Jun; 81(6):1303-7. PubMed ID: 23622774
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer.
Xu S; Yi XM; Zhou WQ; Cheng W; Ge JP; Zhang ZY
Int J Clin Exp Pathol; 2015; 8(11):14335-44. PubMed ID: 26823749
[TBL] [Abstract][Full Text] [Related]
20. Expression profile of prostate-specific antigen messenger RNA assessed by in situ hybridization is a novel prognostic marker for patients with untreated prostate cancer.
Tsurusaki T; Koji T; Sakai H; Kanetake H; Saito Y
Clin Cancer Res; 1998 Sep; 4(9):2187-94. PubMed ID: 9748138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
